• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acasti Pharma (NQ: ACST )

    2.900 -0.030 (-1.02%)
    Streaming Delayed Price Updated: 2:27 PM EDT, Apr 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,491
    Open 2.800
    Bid (Size) 2.800 (1)
    Ask (Size) 2.890 (2)
    Prev. Close 2.930
    Today's Range 2.770 - 3.125
    52wk Range 1.720 - 3.840
    Shares Outstanding 44,612,831
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... 
    Via Benzinga
    Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
    Via Benzinga

    Performance

    YTD
    +5.07%
    +5.07%
    1 Month
    -14.71%
    -14.71%
    3 Month
    +21.34%
    +21.34%
    6 Month
    +19.34%
    +19.34%
    1 Year
    +7.31%
    +7.31%

    More News

    Read More
    Recap: Acasti Pharma Q4 Earnings
    Via Benzinga
    Acasti Pharma's Earnings Outlook
    Via Benzinga
    Why Acasti Pharma (ACST) Stock Is Exploding Higher
    Via Benzinga
    Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Acasti Pharma Reports Third Quarter 2023 Operational Results
    From Acasti Pharma, Inc.
    Via GlobeNewswire
    Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
    From Acasti Pharma, Inc.
    Via GlobeNewswire
    Earnings Scheduled For February 14, 2023
    Via Benzinga
    Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
    From Acasti Pharma, Inc.
    Via GlobeNewswire
    Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
    Via Newsfile
    Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
    From Acasti Pharma, Inc.
    Via GlobeNewswire
    Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
    From Acasti Pharma, Inc.
    Via GlobeNewswire
    Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
    From Acasti Pharma, Inc.
    Via GlobeNewswire
    Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
    Via Benzinga
    Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
    From Acasti Pharma, Inc.
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
    Via Benzinga
    Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.